Innocan Pharma Corporation has received its first fully-granted patent in Mexico for its proprietary cannabis-based pain relief topical. The patent covers a formulation blending cannabidiol with minerals, designed for fast-acting, targeted pain relief. Clinical studies have shown noticeable pain reduction within 20 minutes of application.

The Mexican patent adds to Innocan's growing intellectual property portfolio, which includes previously granted patents in the United States, Russia, and Ukraine. The company also has pending applications across various global jurisdictions. This development positions Innocan for early and strategic access to Latin American markets.

Iris Bincovich, CEO of Innocan Pharma, expressed excitement about the patent approval. Innocan Pharma intends to continue expanding its intellectual property portfolio in other key territories worldwide, reinforcing its leadership in cannabidiol-based wellness innovation.

Innocan Pharma is an innovator in the pharmaceuticals and wellness sectors, focusing on a CBD-loaded liposome drug delivery platform for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products through its BI Sky Global Ltd. subsidiary.

Innocan Pharma's plans to enter the Latin American market are subject to risks and uncertainties, including economic, political, and market conditions, regulatory requirements, and potential disruption of relationships with suppliers, manufacturers, customers, business partners, and competitors. The company cannot assure that any patent will issue as a result of a pending patent application.

There are also risks inherent in product distribution, including import/export matters and the failure to obtain required regulatory approvals. Readers are cautioned not to place undue reliance on forward-looking information, as actual results may vary materially from the forward-looking information.